「the first」の検索結果
21件：11～15件目を表示
-
Management Policy | About Senju | SENJU Pharmaceutical
valuable for society, we are committed to pursuing happiness for all people associated with Senju rather than just becoming a “big company” that pursues only greater growth and increased sales. Action...
https://www.senju.co.jp/english/about/philosophy.html -
g approval in Japan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 anta...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
g approval in Japan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 anta...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
Product Development Policy | Research & Development | SENJU Pharmaceutica
Corporate Strategy DivisionProduct Planning DepartmentDirectorYasunobu Maenaka With the management philosophy of “Good Company” and a company that shapes “Beyond eyesight,” we have developed products ...
http://www.senju.co.jp/english/rd/policy/ -
研究開発体制 | 研究開発活動 | 千寿製薬株式会社
、願いでもあるのです。 研究開発本部 トップメッセージ 執行役員研究開発本部 本部長関弥 卓郎 みなさん、こんにちは。研究開発本部では『他の追随を許さないスピードで、眼疾患患者さまの第一選択薬となる First in Class、Best in Class の製品を提供し続けている』をビジョンに掲げ、日々研究開発活動に取り組んでいます。 私たちは「他の追随を許さないスピード」の実現に向けて、「眼の...
https://www.senju.co.jp/rd/about/